Vapotherm, a global leader in High Flow Therapy (HFT) products, has received clearance from the Food and Drug Administration (FDA) for the Flowrest homecare device.
The Flowrest delivers warmed, humidified high-flow breathing gases to patients via nasal cannula. Utilizing patent pending humidification and breathing circuit technology, the device is designed to maximize ease of use and patient comfort, both of which are critical in homecare and other low acuity settings.
HFT via nasal cannula is utilized in hospitals throughout the world to provide respiratory support for spontaneously breathing adult, pediatric and neonatal patients with a variety of acute or chronic conditions. Clinical practice and research has demonstrated that its use can help clinicians avoid more invasive respiratory therapies. Vapotherm’s gas conditioning technology allows for high flows to be delivered via a simple nasal cannula, allowing patients to avoid the discomfort and confinement of mask therapy
